Jim O'Mara, Neurogastrx CEO
After pandemic delay and a South Korean deal, Boston-area biotech raises Series B with sights on IPO
Two years after snaring a $45 million Series A from a couple of top-flight investors, Neurogastrx was finally ready to put its lead molecule into …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
